Transforming growth factor-β and breast cancer: Lessons learned from genetically altered mouse models

Breast Cancer Research

Volumn 2, Issue 2, 2000, Pages 100-106

  Wakefield, L M ^a   Yang, Y A ^a   Dukhanina, O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dominant negative mutant receptors; Mammary gland; Transforming growth factor ; Transgenic mice; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; BREAST HYPERPLASIA; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; REVIEW;

ANIMALS; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC ENGINEERING; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034468328     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr41     Document Type: Review

References (35)

1. Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary gland development
2. Effects of transforming growth factor β on growth of human mammary epithelial cells in culture
3. TGF-β1-induced inhibition of mouse mammary ductal growth: Developmental specificity and characterization
4. Transforming growth factor-β in breast cancer: A working hypothesis
5. Relationship between TGF-β type II receptor expression and breast cancer risk in women with epithelial hyperplasia lacking atypia
6. Complex role of tumor cell transforming growth factor (TGF)-βs on breast cancer progression
7. Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation
8. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β 1
9. Ectopic TGF β 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population
10. Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation
11. Mammary tumor suppression by transforming growth factor β 1 transgene expression
12. Transforming growth factor-βs in mammary tumorigenesis: Promoters or antipromoters?
13. Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
14. TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-β knockout phenotypes
15. Transforming growth factor-β3 is required for secondary palate fusion
16. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis
17. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor Smad2
18. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
19. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
20. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death
21. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β
22. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction
23. Smad3 mutant mice develop metastatic colorectal cancer
24. Strain dependency of TGF-β1 function during embryogenesis
25. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated
26. Inhibins and activins regulate mammary epithelial cell differentiation through mesenchymal-epithelial interactions
27. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice
28. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene
29. Overexpression of a kinase-deficient transforming growth factor-β type II receptor in mouse mammary stroma results in increased epithelial branching
30. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis
31. The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors
32. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-β type II receptor gene in sporadic human breast cancers
33. Frequency of Smad gene mutations in human cancers
34. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
35. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis